Verve shares first base editing results in humans, suggesting therapy can lower cholesterol in patients with genetic condition
PHILADELPHIA — Verve Therapeutics’ next-generation gene editing treatment lowered cholesterol levels in a handful of patients with heterozygous familial hypercholesterolemia, marking the first time that base editing has been used to directly alter DNA in humans.
The early Phase I data, presented Sunday at the American Heart Association’s scientific meeting, give a glimpse at how the in vivo treatment works in people who have been diagnosed with the genetic disorder that causes high cholesterol and often heart disease at an early age.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
